Literature DB >> 19816170

Role of the pituitary-bone axis in skeletal pathophysiology.

Aliza Imam1, Jameel Iqbal, Harry C Blair, Terry F Davies, Christopher L-H Huang, Alberta Zallone, Mone Zaidi, Li Sun.   

Abstract

PURPOSE OF REVIEW: Embedded within textbooks for decades is the hard fact that releasing hormones from the anterior pituitary, namely, follicle-stimulating hormone, thyroid-stimulating hormone and adrenocorticotropic hormone, stimulate master hormone secretion from target endocrine organs. We propose a paradigm shift in endocrine physiology, which is that these hormones act by design on bone directly, also now considered an endocrine organ. RECENT
FINDINGS: Complementary investigations using mouse genetic and cell biological approaches reveal that follicle-stimulating hormone and thyroid-stimulating hormone act on bone cells directly to regulate bone remodeling and bone mass. Thyroid-stimulating hormone inhibits bone remodeling, whereas follicle-stimulating hormone stimulates it. We also find that the posterior pituitary hormone oxytocin is anabolic to the skeleton.
SUMMARY: An ambitious extrapolation is that a plurality of pituitary hormones acts in concert as part of a 'pituitary-bone' axis to regulate skeletal integrity in health and disease. When dysregulated master hormone levels during hypogonadism and hyperthyroidism cause altered pituitary hormone secretion through hypothalamic feedback, the latter hormones contribute to the skeletal loss.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816170     DOI: 10.1097/MED.0b013e3283328aee

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  5 in total

Review 1.  The role of FSH and TSH in bone loss and its clinical relevance.

Authors:  Manasi Agrawal; Guangyu Zhu; Li Sun; Mone Zaidi; Jameel Iqbal
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

Review 2.  Brain to bone: What is the contribution of the brain to skeletal homeostasis?

Authors:  Anna Idelevich; Roland Baron
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

3.  Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.

Authors:  Murat Zinnuroglu; Aylin Sepici Dincel; Funda Kosova; Vesile Sepici; Gulcin Kaymak Karatas
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

Review 4.  Female reproductive system and bone.

Authors:  Bart L Clarke; Sundeep Khosla
Journal:  Arch Biochem Biophys       Date:  2010-07-14       Impact factor: 4.013

5.  Evaluation of bone texture imaging parameters on panoramic radiographs of patients with Sheehan's syndrome: a STROBE-compliant case-control study.

Authors:  D de Sá Cavalcante; M G da Silva Castro; A R P Quidute; M R A Martins; A M P L Cid; P G de Barros Silva; J Cadwell Williams; F S Neves; T R Ribeiro; F W G Costa
Journal:  Osteoporos Int       Date:  2019-08-02       Impact factor: 4.507

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.